Hong Kong: Artificial Intelligence (AI) has been used by a Hong Kong-based health startup to design a drug. The drug was designed by the AI in just 21 days and it shows potential treatments for fibrosis; a discovery that can speed up the process of designing drugs for several incurable diseases.
Six promising treatments for fibrosis was designed in 21 days by the help of the AI system known as generative tensorial reinforcement learning (GENTRL).
In a paper published in the journal Nature Biotechnology, Insilico Medicine talked about how in the biochemical assays, four compounds were active and two were validated in cell-based assays. Favorable pharmacokinetics in mice was demonstrated by one lead candidate when it was tested.
If a comparison is drawn, testing of thousands of small molecules is the beginning of traditional drug discovery to get to only a few lead-like molecules. Merely about one in 10 of these molecules pass clinical trials in human patients.
CEO of Insilico Medicine, Alex Zhavoronkov said that the development of these first 6 molecules is just the beginning of incredible discoveries.
By making available GENTRL’s source code as open-source on Microsoft-owned repository GitHub and by enabling the rapid discovery of novel molecules, Insilico is ushering new possibilities for the discovery and creation of the latest medicine that can be life-saving whilst treating incurable diseases.
Insilico’s groundbreaking academic research in 2016 has been leveraged by the new technology which